Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
UPDATE: EcoActive™ Bacteriophage Therapy Enters Clinical Trial at the Mount Sinai Hospital
Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial.
Contest For The Best Cartoon Characters Of Bacteriophages
Intralytix is holding a contest for the creation of cartoon characters depicting bacteriophages.
Intralytix Acquires Site for New Headquarters
Intralytix, Inc. announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters.
Intralytix Receives FDA clearance to initiate Phase I / IIa clinical trials
Intralytix, Inc. announced today that it received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical trials at Mount Sinai hospital in New York, NY.